Sign in Subscribe
Cancer research

New Insights into Prostate Cancer Metastasis Detection through Circulating Tumor DNA

Strategic Insights

— 1 min read

Researchers have made a groundbreaking discovery in the field of oncology, specifically in the detection of prostate cancer metastasis using circulating tumor DNA (ctDNA). According to a study published in The Oncologist, Investigators from the University of Foggia in Italy have found that ctDNA acts as an early biomarker of the efficacy of androgen receptor signaling inhibitor (ARSI) therapy. The research, conducted in collaboration with the Ministry of Health, Italy, revealed that ctDNA can predict metastasis burden and radiographic progression disease (PD) in metastatic castration-resistant prostate cancer (mCRPC).

Key Takeaways:

  • The study aimed to investigate the role of ctDNA in predicting metastasis burden and radiographic progression disease (PD) in mCRPC.
  • Researchers collected plasma samples from 112 mCRPC patients with bone, lymph nodal, and visceral metastases and performed targeted next-generation sequencing to assess ctDNA fraction.
  • The study found that early ctDNA variation might reflect changes in metastatic burden and, likely, in bone metastatic patterns on ARSI therapy, allowing for the tracking of disease progression and outcome prediction.
  • The research concluded that circulating tumor DNA can indeed act as an early biomarker of the efficacy of ARSI therapy in patients with mCRPC.
  • The study's findings have significant implications for the development of new diagnostic and therapeutic strategies for patients with prostate cancer.
  • Vincenza Conteduca, University of Foggia, was the lead researcher on the study, which also involved a multidisciplinary team of experts from the University of Foggia and other institutions.

Statistics:

  • 112 patients with metastatic castration-resistant prostate cancer (mCRPC) were included in the study.
  • The study collected plasma samples from patients with bone, lymph nodal, and visceral metastases.
  • Targeted next-generation sequencing was performed on 112 patients with mCRPC.
  • Early ctDNA variation was found to be significantly associated with median ctDNA at baseline, during treatment, and at radiographic progression disease (PD).
  • The study found a correlation between ctDNA dynamics and changes in metastatic burden and bone metastatic patterns on ARSI therapy.

Sources:

  • Conteduca, V., et al. (2025). Changing Metastatic Patterns Associate With Dynamics of Circulating Tumor Dna In Metastatic Castration-resistant Prostate Cancer. The Oncologist, 30(5), 2025.
  • NewsRx. Studies from University of Foggia Describe New Findings in Prostate Cancer (Changing Metastatic Patterns Associate With Dynamics of Circulating Tumor Dna In Metastatic Castration-resistant Prostate Cancer). Health & Medicine Week. June 13, 2025; p 6977.

Read more